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Epidermal Pyridoxal 5'-Phosphate Depletion, Inhibition of DNA 
Synthesis, and Inhibition of the Expression of Ornithine Decarboxylase 
Activity by the Vitamin B-6 Antagonist 4'-Deoxypyridoxine 
MICHAEL J. CONNOR, PH.D. AND NICHOLAS J. LOWE, M.D., M.R.C.P. 
Division of Dermatology, UCLA School of Medicine, Los Angeles, California, U.S.A. 
The induction of ornithine decarboxylase (ODC) activ-
ity may be an essential component of skin tumor pro-
motion. ODC requires pyridoxal5'-phosphate (PLP) as a 
cofactor. We have measured the epidermal PLP concen-
tration and investigated its relationship to DNA synthe-
sis and ODC activity in the hairless mouse. 
The epidermal PLP concentration was approximately 
1.0 11-g/ g. When tape-stripping was used to induce ODC 
activity in the epidermis the concentration of PLP was 
significantly elevated 4.5 h later at the time of peak ODC 
activity and when DNA synthesis was reduced. 
Systemic treatment with the vitamin B-6 antagonist 
4'-deoxypyridoxine (4~DOP) significantly reduced the ep-
idermal PLP concentration and DNA synthesis. The ODC 
activity induced in the epidermis 4.5 h after tape-strip-
ping in 4-DOP-treated mice was only 17% of that induced 
in untreated tape-stripped controls. In in vitro experi-
ments it was shown that while 4-DOP does not inhibit 
ODC activity, a major metabolite of 4-DOP, 4-DOP-phos-
phate (K; .06 mM), does. In mixing experiments it was 
shown that the epidermal extracts from 4-DOP-treated 
mice did not contain significant amounts of ODC inhibi-
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Abbreviations: 
4-DOP: 4'-deoxypyridoxine 
4-DOP-phosphate: 4'-deoxypyridoxine-phosphate 
ODC: ornithine decarboxylase (EC 4.1.1.17, L-ornithine carboxyl-
ase) 
PLP: pyridoxal 5' -phosphate 
tors. 4-DOP may inhibit ODC induction in the epidermis 
by depleting the PLP content. 
The pyridoxine (vitamin B-6) derivative, pyridoxal 5' -phos-
phate (PLP), is a cofactor for several mammalian decarboxy-
lases including the polyamine synthesis enzyme ornithine de-
carboxylase (ODC). ODC activity is induced in mouse skin by 
tumor promoters [1] and polyamine levels are elevated in 
proliferating . tissues (2]. Current evidence indicates that the 
induction of ODC activity, while not necessarily specific for 
tumor promotion, may be an essential component of the process 
(3-5]. If the induction of ODC activity is essential for carcino-
genesis, then inhibitors of ODC should be good candidates as 
antitumor agents. In this respect the irreversible, highly specific 
(suicide) inhibitor of ODC, alpha-difluoromethyl-ornithine, has 
recently been shown to inhibit tumor promotion in mouse skin 
[5,6]. 
Hepatocarcinogenesis is reduced [7,8] and the growth of 
hepatomas severely impaired [9] in pyridoxine deficiency. The 
pyridoxine antagonist 4'-deoxypyridoxine (4-DOP) irihibits tu-
mor growth [10] and has been used in the treatment of adult 
lymphatic leukelnia [11]. Tissue putrescine and spermidine 
levels are reduced in pyridoxine deficiency [12], and the PLP 
concentration may therefore regulate putrescine synthesis. 
Murray and Froscio [13] found that reduced levels of ODC 
activity were induced in the epiderlnis of pyridoxine-deficient 
compared to pyridoxine-replete Inice after treatment with the 
tumor promoter tetradecanoylphorbol-13-acetate. Thus epider-
mal ODC activity is influenced in vivo by the pyridoxine status 
and this may explain in part the anticancer and antiproliferative 
properties of pyridoxine deficiency. 
We have been investigating the possible use of 4-DOP for 
regulating the supply of PLP to the epidermis to control ODC 
activity more directly, and to establish a new route for inhibiting 
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putrescine synthesis and epidermal proliferation. In the present 
study we have measured the PLP concentration of hairless 
mouse epidermis and have investigated its relationship to epi-
dermal DNA synthesis and ODC activity. We report the ability 
of the pyridoxine antagonist 4-DOP to deplete epidermal PLP 
levels, to inhibit DNA synthesis, and to inhibit the expression 
of ODC activity. 
MATERIALS AND METHODS 
Materials 
L-[1- 14C]Ornithine hydrochloride (specific radioactivity 57 Ci/mol), 
[methyVH]thymidine (specific radioactivity 2 Ci/mmol), and NCS 
were bought from Amersham (Arlington Hts, Illinois). L-Ornithine, 
PLP, 4'-deoxypyridoxine, tartaric acid, dithiotlu:eitol, bovine gamma 
globulin, and calf thymus DNA were bought from Sigma (St. Louis, 
Missouri). 4'-Deoxypyridoxine-phosphate (4'-DOP-phosphate) was 
bought from Calbiochem (La Jolla, California). All experiments were 
performed on 8 to 10-week-old skh/HRl hairless female mice originat-
ing from the Skin Cancer Hospital (Temple University, Philadelphia, 
Pennsylvania). 
Preparation of Mouse Epidermis 
Mice were killed by cervical dislocation and the back skins removed. 
To separate off the epidermis each skin was immersed in a water bath 
at 55°C for 30 s, cooled in ice/ water, blotted dry with filter paper, 
placed flat on a cooled glass plate, and the epidermis (0.08-0.15 g) 
scraped off the dermis with a scalpel blade. 
For ODC assay, each epidermis was homogenized in ice-cold 50 mM 
sodium phosphate buffer pH 7.2 (1 ml) containing 0.4 mM PLP and 5 
mM dithiothreitol, with a Brinkman homogenizer, at setting 6, for 15 s. 
The homogenates were centrifuged at 30,000 g for 30 min and the 
supernatants recovered and stored at -70°C until used. The stored 
extracts retained their activity for several months under these condi-
tions. 
To measure DNA synthesis mice were injected 1 h prior to sacrifice 
with 30 flCi [3H]thymidine, the mice killed and the epidermis recovered 
as above, and the DNA extracted and assayed after the method of 
Baird et al [14]. Each epidermis was homogenized in 1 ml ice-cold 0.4 
M perchloric acid with a Brinkman homogenizer, at setting 6, for 30 s. 
After standing the homogenates on ice for 15 min, they were centrifuged 
(1500 rpm), the supernatant removed for PLP assay, and the pellets 
recovered and washed free of unbound ["H]thymidine by resuspending 
in a further 1 ml 0.4 M perchloric acid and recentrifuging, and resus-
pending and recentrifuging twice in absolute ethanol. The pellets were 
then suspended in 2 ml 0.4 M perchloric acid and the DNA hydrolyzed 
by heating at 90°C for 20 min in a block heater. 
Tape-Stripping 
Mice were injected i.p. with chloral hydrate (300 mg/kg body weight) 
15 min before tape-stripping. Since ODC induction by tape-stripping is 
dose-dependent (unpublished observations), each mouse was stripped 
10 times with Scotch Magic Tape. During tape-stripping, strips of tape 
about 10 em long were placed along the back of the mice, pressed down 
firmly to make contact with the skin, and massaged on the skin for 
about 10 s before being removed by a single pull. Each piece of tape 
was used once only. 
ODCAssay 
ODC activity in epidermal samples was determined by measuring 
the release of '''C02 from L-[1-' ''C]ornithine. Incubations were per-
formed in 0.05 M sodium phosphate buffer pH 7.2 containing 5 mM 
dithiothreitol, 0.4 mM PLP, 1 mM L-ornithine, 0.5 ,uCi L-[1-"C]orni-
thine, and 0 to 0.2-ml sample in a final volume of 0.3 ml. 
The reaction mixtures were incubated at 37°C for 1 h in sealed tubes 
fitted with side arms [15]. The released 14C02 was collected directly 
into scintillation vials containing 0.15 ml of NCS, attached to the side 
arms by holed rubber stoppers. The reactions were terminated by 
injecting 2 M citric acid (0.5 ml) through a sleeve stopper in the mouth 
of each tube. 
Total protein in the epidermal extracts was determined with the 
BioRad protein assay (BioRad Laboratories, Richmond, California) 
using bovine gamma globulin as the standard. ODC activities . are 
expressed as nmol C02 released per mg soluble protein per hour. 
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DNA Synthesis 
Total epidermal DNA was determined on aliquots of hydrolyzed 
samples by the diphenylamine reaction using calf thymus DNA as the 
standard. The specific radioactivity of the DNA was determined by 
counting 0.2-ml aliquots of each hydrolyzed sample in a scintillation 
counter. DNA synthesis is expressed as cpm/flg DNA. 
Assay of PLP Levels 
Epidermal PLP was assayed fluorimetrically, after quantitative re-
action with cyanide, by modification of existing literature methods 
[16,17]. The fluorescence assay was employed rather than the enzymic 
methods because of the possible presence of PLP antagonists in the 
extracts. 
PLP determinations were performed directly on the supernatant 
obtained when epidermis was homogenized in 0.4 M perchloric acid and 
centrifuged at 1,500 gas for the DNA synthesis studies. Aliquots (0.3 
ml) of each sample were placed in clean disposable test tubes and 2 ml 
of 0.5 M Na2HPO., added, followed by 0.1 ml of 0.05 M KCN in 0.5 M 
Na2HP04 or 0.1 ml of 0.5 M Na2HPO., only. The contents of the tubes 
were mixed and the tubes stood in a water bath at 50°C for 30 min. 
The tubes were removed, cooled, and 0.6 ml of 1.0 M L-tartaric acid 
added. The fluorescence was read in a Varian SF30 spectrofluorometer 
at an excitation wavelength of 325 nm and an emission wavelength of 
425 nm. The difference in fluorescence of each extract after reaction 
with KCN compared to without KCN was used to calculate the PLP 
content by reference to a standard curve of 0-4 nmol PLP. The 
concentration of the PLP standard was determined exactly by spectro-
photometry using an extinction coefficient of 6, 700 at 295 nm, deter-
mined in 0.4 M perchloric acid. In preliminru·y experiments it was found 
that 4-DOP is not detected and does not intmfere with this assay. 
Statistical Analysis 
The differences among the various treatment groups were compared 
using Student's t-test; values of p < 0.05 were considered significant. 
RESULTS 
Epidermal PLP Content and DNA Synthesis 
The PLP concentrations and rates of DNA synthesis were 
measured in the epidermis from untreated, saline-treated, or 
saline-treated and tape-stripped mice. The mice were killed 4.5 
h after tape-stripping, at the time of peak induction of ODC 
activity [18]. Separate groups of mice were treated with saline 
or saline and tape-stripping, but were killed and the epidermis 
extracted and assayed for ODC activity. The results of these 
experiments are summarized in Table I. The PLP content (1.02 
± .18) and DNA synthesis (67.3 ± 7.3) of epidermis from 
untreated mice (n = 5) was not significantly different from the 
saline-treated control group. In preliminary experiments it was 
found that the chloral hydrate anesthetic used in tape-stripping 
experiments, had no effect on the parameters measured. 
TABLE I. The effect of systemic 4'-deoxypyridoxine on PLP 
concentrations, DNA synthesis, and the induction of ODC activity in 
hairless mouse epidermis 
Treatment DNA synthesis PLP ODC activity (cpm/ l'g) (I'{:/ g) (nmol/mg/ h) 
Saline 71.7 ± 15.8 .97 ± .15 .08 ± .05 
(n = 9) (n= 9) (n = 5) 
4-DOP 33.2 ± 5.6" .51± .11" not determined 
(n = 5) (n = 5) 
Tape-stripped 39.6 ± 2.6" 1.65 ± .356 2.68 ± 1.23 
+saline (n = 10) (n = 10) (n = 5) 
Tape-stripped 35.2 ± 6.6"· c .63 ± .29"· d .47 ± .38'' 
+ 4-DOP (n = 5) (n= 5) (n = 5) 
Each value represents the mean ± SD of samples from n mice. 
" Significantly lower than after saline treatment, p < 0.005. 
b Significantly higher than after saline treatment, p < 0.005. 
c Not significantly different than after 4-DOP or tape-stripping + 
saline treatment. 
d Significantly lower than after tape-stripping + saline treatment, p 
< 0.005; not significantly different from 4-DOP treatment alone. 
• ODC activity induced by tape-stripping was significantly lower after 
4-DOP treatment, p < .005. 
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The PLP concentration found in hairless mouse epidermis 
was about 1 J.lg/g (4 X 10- 6 M) and is about 50% that reported 
for mouse brain and 10% of mouse liver [16] and is similar to 
that of mouse dermis (unpublished observation) . There was a 
significant increase in the PLP concentration 4.5 h after tape-
stripping, at a time when ODC activity was induced and when 
DNA synthesis was still suppressed. The experiment demon-
strated that the epidermal PLP concentration may change in 
response to proliferative stimuli prior to the induction of DNA 
synthesis. 
Systemic 4-DOP and Epidermal PLP, ODC Activity, and 
DNA Synthesis 
Groups of mice were injected i.p. with 4-DOP (150 mg/kg in 
saline) or saline 24 and 4 h prior to killing, and epidermal PLP 
and DNA synthesis determined. The results are presented in 
Table I. 
The epidermal PLP content and DNA synthesis were sig-
nificantly reduced (p < .0005) after 4-DOP treatment. The 
results are interesting in that 4-DOP treatment significantly 
depleted epidermal PLP and induced a corresponding inhibition 
of DNA synthesis. The experiment demonstrated the feasibility 
of manipulating epidermal PLP levels by systemic 4-DOP treat-
ment. 
Two groups of mice were injected with 4-DOP or saline as 
above but tape-stripped 4 h after the second injection to induce 
epidermal ODC activity. The mice were killed 4.5 h later and 
the epidermis extracted and assayed for ODC activity. The 
results are summarized in Table I. The ODC activity induced 
in the epidermis of the 4-DOP-treated mice was significantly 
lower at 17% of the saline-treated tape-stripped controls. 
The Effects of Epidermal Extracts from 4-DOP-Treated 
Mice, of 4-DOP, and of 4-DOP-Phosphate on ODC Activity 
To confirm that the reduced ODC activity induced by tape-
stripping after 4-DOP treatment reflected a real decrease in the 
amount of ODC pres!)nt and was not simply due to inhibition 
of ODC activity in vitro, by the presence of 4-DOP or metabo-
lites in the extracts, mixing experiments were performed. 4-
DOP is metabolized to 4-DOP-phosphate, a potent inhibitor of 
several PLP-requiring decarboxylases [19]. 4-DOP, 4-DOP-
phosphate, and epidermal extracts from mice treated with 4-
DOP prior to tape-stripping were tested as inhibitors of ODC. 
The source of the ODC activity used was a crude extract of 
epidermis from tape-stripped mice. 
ODC activity (0.1 ml; total activity 1.20 nrnol C02!h) was 
incubated with epidermal extract from 4-DOP-treated tape-
stripped mice (0.1 ml; total activity 0.10 nrnol COd h) in the 
standard ODC assay. The total ODC activity of the mixture 
was 1.34 nrnol COd h. Since the activity of the mixture was 
equal to the sum of the activities of the 2 extracts, the extracts 
from the 4-DOP-treated mice do not contain appreciable 
amounts of active ODC inhibitors. 
In other experiments 4-DOP concentrations up to 5 X 10- 3 M 
were found not to inhibit ODC in vitro. In contrast, 4-DOP-
phosphate was a potent ODC inhibitor. The inhibition kinetics 
were examined in detail. Inhibition of ODC activity by 4-DOP-
phosphate obeyed Michaelis-Menton kinetics of the mixed com-
petitive/noncompetitive type with an apparent K; of 6 X 10- 5 
M (the same order of magnitude as the Km for PLP, 3 X 10- 5 MY 
determined using Line-Weaver-Burke plots; ·at higher concen-
trations of 4-DOP-phosphate (> 5 mM) the plots were nonlinear, 
but this may be anticipated in view of the crudity of the enzyme 
preparation. 
DISCUSSION 
In the present study epidermal PLP concentrations have 
been measured in normal and tape-stripped hairless mouse 
epidermis. Tape-stripping removes the outer layers of the stra-
tum corneum and induces a benign epidermal hyperplasia; 
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DNA synthesis is initially inhibited (with a nadir at about 4 h 
after insult) and then increases to a peak at 24 h. Epidermal 
ODC activity is also induced by tape-stripping, peaking 4.5 h 
after insult [18]. The epidermal PLP concentration was in-
creased 4.5 h after tape-stripping, well before the induction of 
DNA synthesis. The raised concentration ofPLP in the epider-
mis when ODC is induced may facilitate putrescine synthesis. 
The depletion of epidermal PLP by systemic 4-DOP treat-
ment may indicate a tissue-specific requirement for PLP or one 
of its congeners by the epidermis, since PLP depletion is not 
seen in other tissues such as liver, kidney, and muscle [20,21]. 
The PLP supply to the epidermis may be particularly crucial, 
since even in chronic vitamin B-6 deficiency hepatic PLP levels 
are reduced to 55-60% of control values [12,21], which is still 5-
6 times higher than in hairless mouse epidermis and more than 
10 times higher than in the epidermis of 4-DOP-treated mice. 
Further studies are required to determine whether the epider-
mis has distinct metabolic or transport requirements for pyri-
doxine derivatives. 
The expression of epidermal ODC activity was inhibited 
following 4-DOP administration. In view of the extremely short 
half-life of ODC this could represent a change in the rate of 
induction or degradation of ODC. Since we could not find 
inhibitors of ODC activity in epidermal extracts from 4-DOP-
treated mice, and the induction of epidermal ODC activity was 
reduced in dietary vitamin B-6 deficiency [13], the primary 
effect on epidermal ODC activity is probably the depletion of 
PLP rather than a direct effect of 4-DOP or one of its metabo-
lites. 
A requirement for PLP in the expression of activity is com-
mon among PLP-requu·ing enzymes [22] and many PLP-re-
quiring enzymes are stabilized by PLP [23,24]. The mechanism 
of stabilization is unclear but may involve induction of confor-
mational changes in the protein structure on the binding of the 
cofactor. Such a conformational change is likely for ODC since 
PLP protects it from proteolysis by trypsin [13]. Hence, in PLP 
deficiency ODC may be destabilized or degraded at an enhanced 
rate. Pyridoxine deficiency has a marked effect on the induction 
of several hepatic and hepatoma PLP-requiring enzymes 
[25,26], and it is possible that PLP may be required for the 
induction of ODC per se. 
Even under conditions where ODC activity was not induced, 
4-DOP treatment decreased the epidermal PLP concentration 
and inhibited DNA synthesis. The relationship between PLP 
and epidermal proliferation is evidently complex. The manip-
ulation of epidermal PLP levels using pyridoxine antagonists is 
feasible and may result in the inhibition of the expression of 
ODC activity. 
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The Relationship Between the In Vitro Activity of 3/J-Hydroxysteroid 
Dehydrogenase 4 4- 5-Isomerase in Human Sebaceous Glands and Their 
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3/J-Hydroxysteroid dehydrogenase .14-5-isomerase (.15-
3/J-HSD) catalyzes an early step in the synthesis of t es-
tosterone from dehydroepiandrosterone (DHA). We 
compared enzyme activity in back skin biopsies with 
sebum excretion rate (SER) in 14 individuals. The rate of 
conversion of [7a-3H]DHA into [3H]-4-androstene-3,17-
dione was measured in cryostat sections of skin and 
compared with the sebaceous gland content of the same 
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biopsies. Reaction rate was proportional t o the volume 
of sebaceous gland tissue in the sections . Enzyme activ -
ity was absent from sections without histologically iden-
tifiable sebaceous gland tissue. This suggests that the 
~5-3/J-HSD is localized in sebaceous glands. SER, m eas-
ured by a modified photometric technique at the biopsy 
site, correlated highly with sebaceous gland volume and 
with the rate of conversion of DHA into androstenedione 
in the biopsy. For each biopsy, specific activity of .15-3/J-
HSD in sebaceous glands was calculated by dividing the 
rate of formation of PH]-4-androstene-3,17 -dione by se-
baceous gland volume. Specific activity of ~5-3/J-HSD did 
not correlate significantly with SER, suggesting that 
variations in concentration of ~5-3/J-HSD in sebaceous 
glands probably do not underlie variations in sebaceous 
gland activity. 
The weak androgen dehydroepiandrosterone (DHA) stimu-
lates sebaceous gland secretion in humans [1,2]. The increase 
